Prospects and perils of retrospective risk assessment of erythropoiesis-stimulating agents

Am J Hematol. 2008 Sep;83(9):693-4. doi: 10.1002/ajh.21244.
No abstract available

Publication types

  • Comment
  • Editorial

MeSH terms

  • Anemia / drug therapy
  • Anemia / etiology
  • Clinical Trials as Topic / statistics & numerical data
  • Disease-Free Survival
  • Follow-Up Studies
  • Greece / epidemiology
  • Hematinics / adverse effects*
  • Hematinics / therapeutic use
  • Humans
  • Multiple Myeloma / complications
  • Multiple Myeloma / mortality
  • Multiple Myeloma / pathology
  • Neoplasm Staging
  • Prognosis
  • Research Design
  • Retrospective Studies
  • Risk
  • Risk Factors
  • Selection Bias
  • Survival Analysis
  • Treatment Outcome

Substances

  • Hematinics